FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2073661853> ?p ?o ?g. }

• W2073661853 endingPage "206" @default.
• W2073661853 startingPage "199" @default.
• W2073661853 abstract "Developmental Medicine & Child NeurologyVolume 40, Issue 3 p. 199-206 Free Access Autoimmune and genetic disorders at the neuromuscular junction The 1997 Ronnie Mac Keith Lecture John Newsom-Davis MD FRCP FRS, John Newsom-Davis MD FRCP FRS Neurosciences Group, Institute of Molecular Medicine, University of Oxford, John Raddiffe Hospital, Oxford OX3 9DS, UKSearch for more papers by this author John Newsom-Davis MD FRCP FRS, John Newsom-Davis MD FRCP FRS Neurosciences Group, Institute of Molecular Medicine, University of Oxford, John Raddiffe Hospital, Oxford OX3 9DS, UKSearch for more papers by this author First published: 12 November 2008 https://doi.org/10.1111/j.1469-8749.1998.tb15448.xCitations: 8AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat References 1 Newsom-Davis J. (1997) Autoantibody-mediated channelopathies at the neuromuscular junction. Neuroscientist 3: 337– 46. 2 Simpson JA. (1960) Myasthenia gravis: a new hypothesis. Scottish Medical Journal 5: 419– 39. 3 Newsom-Davis J, Vincent A, Willcox N. (1993) Autoimmune disorders of the neuromuscular junction. In: PJ Lachmann, DK Peters, FS Rosen, MJ Walport, editors. Clinical Aspects of Immunology Oxford: Blackwell Scientific Publications. p 2091– 111. 4 Scadding GK, Vincent A, Newsom-Davis J, Henry K. (1981) Acetylcholine receptor antibody synthesis by thymic lymphocytes: correlation with thymic histology. Neurology 31: 935– 43. 5 Rodriguez M, Gomez MR, Howard FM, Taylor WF. (1983) Myasthenia gravis in children: long term follow-up. Annals of Neurology 13: 504– 10. 6 Palace J, Newsom-Davis J, Lecky B. Myasthenia Gravis Study Group. A randomised double-blind controlled trial of prednisolone and azathioprine versus prednisolone alone in myasthenia gravis. Neurology (Forthcoming). 7 Namba T, Brown SB, Grob D. (1970) Neonatal myasthenia gravis: report of two cases and review of the literature. Paediatrics 43: 488– 504. 8 Barnes PR, Kanabar DJ, Brueton L, Newsom-Davis J, Huson SM, Mann NP, Hilton-Jones D. (1995) Recurrent congenital arthrogryposis leading to a diagnosis of myasthenia gravis in an initially asymptomatic mother. Neuromuscular Disorders 5: 59– 65. 9 Vincent A, Newland C, Brueton L, Beeson D, Riemersma S, Huson SM, Newsom-Davis J. (1995) Arthrogryposis multiplex congenita with maternal autoantibodies specific for a fetal antigen. Lancet 346: 24– 5. 10 Riemersma S, Vincent A, Beeson D, Newland C, Hawke S, der Garabedian B Vernet, Eymard B, Newsom-Davis J. (1996) Association of arthrogryposis multiplex congenita with maternal antibodies inhibiting fetal acetylcholine receptor function. Journal of Clinical Investigation 98: 2358– 63. 11 Mier AK, Havard CWH. (1985) Diaphragmatic myasthenia in mother and child. Postgraduate Medical Journal 61: 725– 7. 12 Mossman S, Vincent A, Newsom-Davis J. (1986) Myasthenia gravis without acetylcholine receptor antibody: a distinct disease entity. Lancet i: 116– 9. 13 Barrert-Jolley R, Byrne N, Vincent A, Newsom-Davis J. (1994) Plasma from patients with seronegative myasthenia gravis inhibit nAChR responses in TE671/RD muscle cell line. Pflugers Archive 428: 492– 8. 14 Chelmicka-Schorr E, Bernstein LP, Zurbrugg EB, Hurtenlocher PR. (1979) Eaton-Lambert syndrome in a 9-year-old girl. Archives of Neurology 36: 572– 4. 15 O'Neill JH, Murray NM, Newsom-Davis J. (1988) The Lambert-Eaton myasthenic syndrome. A review of 50 cases. Brain 111: 577– 96. 16 Lang B, Newsom-Davis J. (1995) Immunopathology of the Lambert-Eaton myasthenic syndrome. Springer Seminars in Immunopathology 17: 3– 15. 17 Roberts A, Perera S, Lang B, Vincent A, Newsom-Davis J. (1985) Paraneoplastic myasthenic syndrome IgG inhibits 5Ca2+ flux in a human small-cell carcinoma line. Nature 317: 737– 9. 18 Chalk CH, Murray NM, Newsom-Davis J, O'Neill JH, Spiro SG. (1990) Response of the Lambert-Eaton myasthenic syndrome to treatment of associated small-cell lung carcinoma. Neurology 40: 1552– 6. 19 Motomura M, Johnston I, Lang B, Vincent A, Newsom-Davis J. (1995) An improved diagnostic assay for Lambert-Eaton myasthenic syndrome. Journal of Neurology Neurosurgery and Psychiatry 58: 85– 7. 20 Lundh H, Nilsson O, Rosen I. (1984) Treatment of Lambert-Eaton syndrome: 3,4-diaminopyridine and pyridostigmine. Neurology 34: 1324– 30. 21 Newsom-Davis J, Murray NM. (1984) Plasma exchange and immunosuppressive drug treatment in the Lambert-Eaton myasthenic syndrome. Neurology 34: 480– 5. 22 Bain PG, Motomura M, Newsom-Davis J, Misbah SA, Chapel HM, Lee ML, Vincent A, Lang B. (1996) Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Neurology 47: 678– 83. 23 Sinha S, Newsom-Davis J, Mills K, Byrne N, Lang B, Vincent A. (1991) Autoimmune aetiology for acquired neuromyotonia (Isaacs syndrome). Lancet 338: 75– 7. 24 Newsom-Davis J, Mills KR. (1993) Immunological associations of acquired neuromyotonia (Isaacs syndrome): report of 5 cases and literature review. Brain 116: 453– 69. 25 Isaacs H. (1961) A syndrome of continuous muscle-fibre activity. Journal of Neurology Neurosurgery and Psychiatry 24: 319– 25. 26 Shillito P, Molenaar PC, Vincent A, Leys K, Zheng W, van den Berg RJ, Plomp JJ, Van Kempen GThH, Wintzen AR, van Dijk G, Newsom-Davis J. (1995) Acquired neuromyotonia: evidence for autoantibodies directed against K+ channels of peripheral nerves. Annals of Neurology 38: 714– 22. 27 Hart IK, Waters C, Vincent A, Newland C, Beeson D, Pongs O, Morris C, Newsom-Davis J. (1996) Autoantibodies detected to expressed K+ channels are implicated in neuromyotonia. Annals of Neurology 41: 238– 46. 28 Shillito P, Vincent A, Newsom-Davis J. (1993) Congenital myasthenic syndromes. Neuromuscular Disorders 3: 183– 90. 29 Engel AG, Ohno K, Bouzat C, Sine SM, Griggs RC. (1996) End-plate acetylcholine receptor deficiency due to nonsense mutations in the e-subunit. Annals of Neurology 40: 810– 7. 30 Croxen R, Beeson D, Vincent A, Newsom-Davis J. (1996) Congenital myasthenic syndrome with a single nucleotide deletion at the intron/exon boundary in exon 12 of the gene encoding the acetylcholine receptor e-subunit. Annals of Neurology 40: 513. 31 Palace J, Wiles CM, Newsom-Davis J. (1991) 3,4-diaminopyridine in the treatment of congenital (hereditary) myasthenia. Journal of Neurology Neurosurgery and Psychiatry 54: 1069– 72. 32 Engel AG, Lambert EH, Mulder DM, Torres CF, Sahashi K, Bertorini TE, Whitaker JN. (1982) A newly recognized congenital myasthenic syndrome attributed to a prolonged open time of the acetylcholine-induced ion channel. Annals of Neurology 11: 553– 69. 33 Oosterhuis HJ, Newsom-Davis J, Wokke JH, Molenaar PC, Weerden TV, Oen BS, Jennekens FG, Veldman H, Vincent A, Wray DW. (1987) The slow-channel syndrome. Two new cases. Brain 110; 1061– 79. 34 Sine SM, Ohno K, Bouzat C, Auerbach A, Milone M, Pruitt JN, Engel AG. (1995) Mutation of the acetylcholine receptor α-subunit causes a slow-channel myasthenic syndrome by enhancing agonist binding affinity. Neuron 15: 229– 39. 35 Gomez CM, Maselli R, Gammack J, Lasalde J, Tamamizu S, Cornblath DR, Lehar M, McNamee M, Kuncl RW. (1996) A β-subunit mutation in the acetylcholine recpetor channel gate causes severe slow-channel syndrome. Annals of Neurology 39: 712– 23. 36 Engel AG, Ohno K, Milone M, Wang H-L, Nakano S, Bouzat C, Pruitt JN, Hutchinson DO, Brengman JM, Bren N, Sieb JP, Sine SM. (1996) New mutations in acetylcholine receptor subunit genes reveal heterogeneity in the slow-channel congenital myasthenic syndrome. Human Molecular Genetics 5: 1217– 27. 37 Croxen R, Newland C, Beeson D, Oosterhuis H, Chauplannaz G, Vincent A, Newsom-Davis J. (1997) Mutations in different functional domains of the human muscle acetylcholine receptor α-subunit in patients with the slow-channel congenital myasthenic syndrome. Human Molecular Genetics 6: 767– 74. 38 Engel AG, Llambert EH, Gomez MR. (1977) A new myasthenic syndrome with end-plate acetylcholinesterase deficiency, small nerve terminals, and reduced acetylcholine release. Annals of Neurology 1: 315– 30. 39 Camp S, Bon S, Li Y, Getman DK, Engel AG, Massoulie J, Taylor P. (1995) Patients with congenital myasthenia associated with end-plate acetylcholinesterase deficiency show normal sequence, mRNA splicing, and assembly of catalytic-subunit. Journal of Clinical Investigation 95: 333– 40. 40 Engel AG, Uchitel OD, Walls TJ, Nagel A, Harper CM, Bodensteiner J. (1993) Newly recognized congenital myasthenic syndrome associated with high conductance and fast closure of the acetylcholine receptor channel. Annals of Neurology 34: 38– 47. 41 Mora M, Lambert EH, Engel AG. (1987) Synaptic vesicle abnormality in familial infantile myasthenia. Neurology 37: 206– 14. Citing Literature Volume40, Issue3March 1998Pages 199-206 ReferencesRelatedInformation" @default.
• W2073661853 created "2016-06-24" @default.
• W2073661853 creator A5019704377 @default.
• W2073661853 date "2008-11-12" @default.
• W2073661853 modified "2023-10-18" @default.
• W2073661853 title "Autoimmune and genetic disorders at the neuromuscular junction The 1997 Ronnie Mac Keith Lecture" @default.
• W2073661853 cites W1545220630 @default.
• W2073661853 cites W1963558808 @default.
• W2073661853 cites W1964333142 @default.
• W2073661853 cites W1973409912 @default.
• W2073661853 cites W1979407612 @default.
• W2073661853 cites W1985828083 @default.
• W2073661853 cites W1999270192 @default.
• W2073661853 cites W2005175773 @default.
• W2073661853 cites W2006498901 @default.
• W2073661853 cites W2008830992 @default.
• W2073661853 cites W2017164915 @default.
• W2073661853 cites W2020140032 @default.
• W2073661853 cites W2027444823 @default.
• W2073661853 cites W2031000302 @default.
• W2073661853 cites W2032733145 @default.
• W2073661853 cites W2036137292 @default.
• W2073661853 cites W2036565576 @default.
• W2073661853 cites W2042683072 @default.
• W2073661853 cites W2046048250 @default.
• W2073661853 cites W2047176804 @default.
• W2073661853 cites W2055736226 @default.
• W2073661853 cites W2063797334 @default.
• W2073661853 cites W2069071843 @default.
• W2073661853 cites W2069618472 @default.
• W2073661853 cites W2078654174 @default.
• W2073661853 cites W2079684466 @default.
• W2073661853 cites W2079990078 @default.
• W2073661853 cites W2091502170 @default.
• W2073661853 cites W2091989665 @default.
• W2073661853 cites W2104669063 @default.
• W2073661853 cites W2114039041 @default.
• W2073661853 cites W2119790118 @default.
• W2073661853 cites W2141862841 @default.
• W2073661853 cites W2170247488 @default.
• W2073661853 cites W2273297484 @default.
• W2073661853 cites W2326269142 @default.
• W2073661853 cites W2343563134 @default.
• W2073661853 cites W2742110424 @default.
• W2073661853 doi "https://doi.org/10.1111/j.1469-8749.1998.tb15448.x" @default.
• W2073661853 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9566659" @default.
• W2073661853 hasPublicationYear "2008" @default.
• W2073661853 type Work @default.
• W2073661853 sameAs 2073661853 @default.
• W2073661853 citedByCount "9" @default.
• W2073661853 countsByYear W20736618532014 @default.
• W2073661853 countsByYear W20736618532020 @default.
• W2073661853 countsByYear W20736618532022 @default.
• W2073661853 crossrefType "journal-article" @default.
• W2073661853 hasAuthorship W2073661853A5019704377 @default.
• W2073661853 hasConcept C169760540 @default.
• W2073661853 hasConcept C2777240379 @default.
• W2073661853 hasConcept C71924100 @default.
• W2073661853 hasConcept C86803240 @default.
• W2073661853 hasConceptScore W2073661853C169760540 @default.
• W2073661853 hasConceptScore W2073661853C2777240379 @default.
• W2073661853 hasConceptScore W2073661853C71924100 @default.
• W2073661853 hasConceptScore W2073661853C86803240 @default.
• W2073661853 hasIssue "3" @default.
• W2073661853 hasLocation W20736618531 @default.
• W2073661853 hasLocation W20736618532 @default.
• W2073661853 hasOpenAccess W2073661853 @default.
• W2073661853 hasPrimaryLocation W20736618531 @default.
• W2073661853 hasRelatedWork W1484101299 @default.
• W2073661853 hasRelatedWork W1488847214 @default.
• W2073661853 hasRelatedWork W1825390396 @default.
• W2073661853 hasRelatedWork W1978429482 @default.
• W2073661853 hasRelatedWork W1985913168 @default.
• W2073661853 hasRelatedWork W2064212639 @default.
• W2073661853 hasRelatedWork W2080623230 @default.
• W2073661853 hasRelatedWork W2105221640 @default.
• W2073661853 hasRelatedWork W2810229806 @default.
• W2073661853 hasRelatedWork W4200149011 @default.
• W2073661853 hasVolume "40" @default.
• W2073661853 isParatext "false" @default.
• W2073661853 isRetracted "false" @default.
• W2073661853 magId "2073661853" @default.
• W2073661853 workType "article" @default.